Sciwind Biosciences Secures Approval for Ecnoglutide Injection for Weight Management in China Ecnoglutide injection, approved by the NMPA, offers an innovative solution for weight management in overweight Chinese adults, achieving significant weight loss.

Sciwind Biosciences Secures Approval for Ecnoglutide Injection for Weight Management in China #China #Hangzhou #NMPA #Ecnoglutide #Sciwind

A Promising Path Forward in Obesity Pharmacotherapy: Ecnoglutide and the Evolution of GLP-1R Agonist Design Announcing a new article publication for BIO Integration journal.  This article reviews robust evidence from a large, multicenter, randomized, placebo-controlled study in Chinese adults with overweigh...

A randomized clinical trial exploring the efficacy of #ecnoglutide, a novel cyclic #adenosine #monophosphate (cAMP)-biased #GLP-1RA, in #obesity without diabetes.

#OpenAccess: bio-integration.org/glp1ra-ecnog...

André J Scheen comments on:
#Ecnoglutide, a biased #GLP-1 receptor agonist as a potential new player for type 2 #diabetes management?
thelancet.com/journals/lan... #T2D

#MedSky #EndoSky

Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-w... Once-weekly ecnoglutide 0·6 mg and 1·2 mg were non-inferior to dulaglutide 1·5 mg in reducing HbA1c in adults with type 2 diabetes and elevated glucose concentrations on metformin monotherapy. Althoug...

New Research:
Once-weekly #ecnoglutide 0·6 mg and 1·2 mg were non-inferior to dulaglutide 1·5 mg in reducing HbA1c in adults with type 2 #diabetes and elevated glucose concentrations on metformin monotherapy thelancet.com/journals/lan...
cAMP-biased #GLP-1 receptor agonist #T2D

#MedSky #EndoSky

In adults with #obesity or #overweight without diabetes (type 1 or 2), individuals administered #ecnoglutide had superior & sustained reduction in bodyweight vs placebo with a favourable safety profile, supporting its potential use for weight management thelancet.com/journals/lan...
#MedSky #EndoSky

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety pro...

New—Efficacy and safety of a biased GLP-1 receptor agonist #ecnoglutide in adults with #overweight or #obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial thelancet.com/journals/lan...
#ADA2025 @AmDiabetesAssn #ADASciSessions

#MedSky #EndoSky